A gateway to UK Biotechnology
Earlier identification of disease risk and diagnosis, through genetic screening
New treatments for previously untreatable conditions.
Reduced reliance on fossil fuels through biologically-produced chemicals and fuels
A sustainable future
Why the UK?
4 of the world's top 10 universities are in the UK
The UK government has committed to life sciences as a key sector for post-covid recovery
UK is number one cluster in Europe and is third globally
Backed by great science
Why New Grounds?
We are building a portfolio-first venture capital fund
On average, first time funds outperform mature funds
We do not think outside of the box, we remove it
A new perspective
Developed proprietary bioreactor for manufacture and scale up of patient derived organoids (PDOs) for high throughput screening. Industry leader in colorectal cancer PDOs with new cell lines being developed.
Novel graphene-based biosensor. This team has has developed a low-cost biosensor for use in analysing compound concentrations during drug development and production.
Led by Professor Helen McCarthy of Queen's University Belfast, pHion has developed the peptide based RALA platform for precision delivery of therapeutic vaccines.